Tuesday, December 13, 2005
Venture Capitol
http://www.alwayson-network.com/comments.php?id=P13106_0_7_0_C
"Medical device investing will remain strong, with valuations for late stage deals continuing to heat up, mainly due to positive liquidity events. The life science side will be more mixed with investments funneling into two main categories: licensing/roll-up plays where the VC acts more like a buyout firm and platform-to-product plays where the VC invests early and the company goes from IP to product."—Mike Carusi, general partner Advanced Technology Ventures
http://www.atvcapital.com/
"Medical device investing will remain strong, with valuations for late stage deals continuing to heat up, mainly due to positive liquidity events. The life science side will be more mixed with investments funneling into two main categories: licensing/roll-up plays where the VC acts more like a buyout firm and platform-to-product plays where the VC invests early and the company goes from IP to product."—Mike Carusi, general partner Advanced Technology Ventures
http://www.atvcapital.com/
